1[1]Burch JW,Stanford N,majerus PW.Inhibition of platelet prostaglandin synthetase by oral aspirin[J].J Clin Invest,1978,61:314-319.
2[2]Roth GJ,Majerus PW.The mechanism of the effect of aspirin on human platelets,I:acetylation of a particulate fraction protein[J].J Clin Invest,1975,56:624-632.
3[3]Vane JR.Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs[J].Nature New Biol,1971,231-232.
4[4]Fourth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy.Chest physicians consensus conference on antithrombotic therapy[J].Chest,1995,108(Suppl):225 s-522 s.
5[5]Hirsh J,Dalen JE,Fuster V,et al.Aspirin and other platelet active drugs:the relationship between dose,effectiveness,and side effects[J].Chest.1992,102(Suppl):327 S-336 s.
7[7]Lembo JN,Black AJ,Roubin GS,et al.Does the addition of dipyridamole to aspirin decrease acute coronary angioplasty complications? The results of a prospective randomized clinical trials[J].Am J Cardiol,1990,65:422-437.
8[8]Clowes AW,Clowes MM,Fingerle J,et al.Kinetics of cellular proliferation after arterial injury:V Role of acute distension in the induction of smooth muscle cell proliferation[J].Lab Invest.1989,60:360-372.
9[9]Balsano F,Rizzo P,Violi F,et al.Antiplatelet treatment with ticlopidine in unstable angia:a controlled multicenter clinical trial:the studio della ticlopidine nell angina instabile group[J].Circulation,1990,82:17-26.
10[10]Love BB,Biller J,Gent M.Adverse haematological effects of ticolopidine.prevention,recognition and management[J].Drug Safety,1998,19:89-98.
